Výsledky vyhledávání

Randomised phase II study comparing topotecan/carboplatin administration for 5 versus 3 days in the treatment of extensive-stage small-cell lung cancer

Autor: J Dethling, R. Lorenz, U. Seifart, K Hans, T Fink, M. Wolf, Carmen Schade-Brittinger, G. Koschel, H. Schroeder, C. Mueller

Publikováno v: Annals of Oncology. 18:104-109

Background: Topotecan is an active drug in small-cell lung cancer (SCLC). In our previous study, a combination of topotecan with cisplatin was associated with a median overall survival of 7.6 or 8.7 months, depending on the duration of treatment. We

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c4b600509671a3fad90e1534ec83c695
https://doi.org/10.1093/annonc/mdl353

Zobrazit plný text záznamu

Ifosfamide, carboplatin and etoposide combined with 41.8°C whole body hyperthermia for malignant pleural mesothelioma

Autor: K. Dalhoff, U. Gatzemeier, E.-M. Ehlers, R Zumschlinge, S.O. Peters, G. J. Wiedemann, Th. Kohlmann, K. Eberhardt, S. Hegewisch-Becker, A Demedts, I. Bruns, Y Gruber, H.I Robins, E. Kaukel, G. Koschel, A. Bakhshandeh, Anne M. Traynor

Publikováno v: Lung Cancer. 39:339-345

We performed a phase II study combining 41.8 degrees C whole body hyperthermia with ICE chemotherapy, i.e. ifosfamide (5 g/m(2)), carboplatin (300 mg/m(2)) and etoposide (150 mg/m(2) on days 2 and 3), administered every 4 weeks, for patients with mal

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a93ea1e3ea439060ebd2dcec939fb7ca
https://doi.org/10.1016/s0169-5002(02)00536-6

Zobrazit plný text záznamu

Long-term survival in SCLC after treatment with paclitaxel, carboplatin and etoposide—A phase II study

Autor: E. Kaukel, Sybill Hessler, Ulrich Gatzemeier, G. Koschel, Franziska Grunwald, Martin Reck, Joachim von Pawel, Urzula Jagos

Publikováno v: Lung Cancer. 39:63-69

Purpose: We evaluated the toxicity and feasibility of adding paclitaxel to a standard platinum/etoposide regimen in the first-line treatment of patients with small cell lung cancer (SCLC). Patients and methods: Eighty-nine patients with limited disea

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5c03a088dc4c74f61671b7a7edc8988d
https://doi.org/10.1016/s0169-5002(02)00383-5

Zobrazit plný text záznamu

Effects of granulocyte-macrophage colony-stimulating factor and dose intensification of V-ICE chemotherapy in small-cell lung cancer: a prospective randomized study of 300 patients

Autor: W Pfeifer, G. Koschel, J. Frisch, M. von Eiff, Nick Thatcher, William P. Steward, R. de Wit, J Fennelly, J. von Pawel, U. Gatzemeier, Penella J. Woll, Jaap Verweij, Luke Clancy

Publikováno v: Scopus-Elsevier
Journal of Clinical Oncology, 16(2), 642-650. American Society of Clinical Oncology
Europe PubMed Central

PURPOSE To assess whether granulocyte-macrophage colony-stimulating factor (GM-CSF) reduces the toxicity of chemotherapy and alters delivered dose-intensity. To assess the feasibility of dose-intensification of chemotherapy in small-cell lung cancer

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d648c37afe6531c1b9137e6751b04963
https://doi.org/10.1200/jco.1998.16.2.642

Zobrazit plný text záznamu

A phase II study of pirarubicin in malignant pleural mesothelioma

Autor: U. Gatzemeyer, G. Koschel, E. Kaukel, E. Salewski

Publikováno v: Cancer. 66:651-654

Thirty-five non-pretreated patients (29 male, six female) with malignant pleural mesothelioma, median age of 68.5 years (range, 29 to 78 years) and a median performance status of 80% (range, 60% to 100%) were treated with 70 mg/m2 Pirarubicin. The tr

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::6f3807c1c657c4fc7107482279f707fd
https://doi.org/10.1002/1097-0142(19900815)66:4<651::aid-cncr2820660408>3.0.co

Zobrazit plný text záznamu

[Chemotherapy of advanced non-small-cell and small-cell bronchial carcinoma with bendamustine--a phase II study]

Autor: M, Reck, B, Haering, G, Koschel, E, Kaukel, J, von Pawel, U, Gatzemeier

Publikováno v: Pneumologie (Stuttgart, Germany). 52(10)

In the palliative treatment of advanced SCLC and NSCLC there is a big need for effective and well tolerable drugs. Bendamustin is an alcylatic agent which had shown activity in the treatment of Non Hodgkin- and Hodgkin-Lymphoma as well as in the trea

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::a9ea36124a0b45053987b66caa44913c
https://pubmed.ncbi.nlm.nih.gov/9847635

Zobrazit plný text záznamu

Paclitaxel, carboplatin, and oral etoposide: a phase II trial in limited-stage small cell lung cancer

Autor: U, Gatzemeier, U, Jagos, E, Kaukel, G, Koschel, J, von Pawel

Publikováno v: Seminars in oncology. 24(4 Suppl 12)

Carboplatin/etoposide is an active regimen in the treatment of small cell lung cancer. This phase II trial evaluated whether adding paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) to this two-drug combination might increase its effica

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::639857fc1d6025a4c3e17bce5eb4328c
https://pubmed.ncbi.nlm.nih.gov/9331141

Zobrazit plný text záznamu

Paclitaxel and cisplatin in patients with non-small cell lung cancer: results of a phase II trial

Autor: J, von Pawel, H, Wagner, N, Niederle, A, Heider, G, Koschel, E, Gromotka, M, Hanske

Publikováno v: Seminars in oncology. 23(5 Suppl 12)

We performed a clinical phase II trial of the combination of paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) and cisplatin in patients with locally advanced (stage IIIB) or metastatic non-small cell lung cancer (NSCLC), using a 3-hour

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::f4204ab49ae95b8ba664df4bebe4a0fc
https://pubmed.ncbi.nlm.nih.gov/8941403

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání